Gilead Sciences, Inc. (GILD)
167.95
-1.78
(-1.05%)
USD |
NASDAQ |
Nov 12, 16:00
168.74
+0.79
(+0.47%)
After-Hours: 20:00
Gilead Sciences EPS Diluted (Quarterly) : 1.942 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.942 |
| June 30, 2026 | -8.444 |
| March 31, 2026 | 1.612 |
| December 31, 2025 | 1.742 |
| September 30, 2025 | 2.434 |
| June 30, 2025 | 1.562 |
| March 31, 2025 | 1.044 |
| December 31, 2024 | 1.416 |
| September 30, 2024 | 1.005 |
| June 30, 2024 | 1.290 |
| March 31, 2024 | -3.344 |
| December 31, 2023 | 1.138 |
| September 30, 2023 | 1.734 |
| June 30, 2023 | 0.8307 |
| March 31, 2023 | 0.801 |
| December 31, 2022 | 1.298 |
| September 30, 2022 | 1.419 |
| June 30, 2022 | 0.9079 |
| March 31, 2022 | 0.0151 |
| December 31, 2021 | 0.3027 |
| September 30, 2021 | 2.054 |
| June 30, 2021 | 1.208 |
| March 31, 2021 | 1.37 |
| December 31, 2020 | 1.232 |
| September 30, 2020 | 0.2855 |
| Date | Value |
|---|---|
| June 30, 2020 | -2.661 |
| March 31, 2020 | 1.221 |
| December 31, 2019 | 2.118 |
| September 30, 2019 | -0.9195 |
| June 30, 2019 | 1.472 |
| March 31, 2019 | 1.539 |
| December 31, 2018 | 0.0023 |
| September 30, 2018 | 1.604 |
| June 30, 2018 | 1.39 |
| March 31, 2018 | 1.17 |
| December 31, 2017 | -2.957 |
| September 30, 2017 | 2.061 |
| June 30, 2017 | 2.333 |
| March 31, 2017 | 2.047 |
| December 31, 2016 | 2.342 |
| September 30, 2016 | 2.487 |
| June 30, 2016 | 2.581 |
| March 31, 2016 | 2.526 |
| December 31, 2015 | 3.181 |
| September 30, 2015 | 3.061 |
| June 30, 2015 | 2.917 |
| March 31, 2015 | 2.762 |
| December 31, 2014 | 2.184 |
| September 30, 2014 | 1.669 |
| June 30, 2014 | 2.196 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 18.45 |
| AbbVie, Inc. | 2.373 |
| Biogen, Inc. | -0.1394 |
| Vertex Pharmaceuticals, Inc. | 2.561 |
| Amgen, Inc. | 7.077 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 2.429B |
| Revenue (Quarterly) | 8.304B |
| Total Expenses (Quarterly) | 5.875B |
| Enterprise Value | 226.62B |
| Gross Profit Margin (Quarterly) | 81.09% |
| Profit Margin (Quarterly) | 29.25% |
| Earnings Yield | -1.87% |
| Operating Earnings Yield | 5.68% |
| Normalized Earnings Yield | 2.721 |